Need help? Contact our team
Magnesium glycinate (also known as magnesium bisglycinate) is a chelated mineral where elemental magnesium is bonded to two glycine amino acid molecules. This unique molecular structure sets it apart from other magnesium forms commonly found in the nutraceutical market.
Why chelation matters: The glycine-magnesium bond protects the mineral throughout the gastrointestinal tract, preventing interaction with food components (phytates, oxalates, fiber) that typically inhibit absorption. The dipeptide transport mechanism then shuttles the intact chelate across the intestinal wall—bypassing the mineral antagonism that plagues oxide and citrate forms.
Differentiation from other magnesium salts:
| Form | Elemental Mg | Absorption Rate | GI Tolerance |
|---|---|---|---|
| Magnesium Glycinate | 14–20% | Very High (chelated) | Excellent |
| Magnesium Citrate | 16% | Moderate | Moderate (osmotic) |
| Magnesium Oxide | 60% | Very Low (4%) | Poor |
| Magnesium Malate | 15% | High | Good |
| Magnesium Taurate | 8–10% | High | Good |
| Magnesium Chloride | 12% | High | Moderate |
Key insight: While oxide contains more elemental magnesium per gram, glycinate delivers significantly more actual magnesium to tissues due to superior absorption kinetics.
| Physiological Role | Mechanism |
|---|---|
| Enzyme cofactor | Activates >300 enzymes (ATP synthesis, protein production, DNA repair) |
| Ion channel regulation | Modulates NMDA receptor excitability (neuroprotection) |
| Muscle contraction | Antagonizes calcium at troponin C (relaxation phase) |
| Neurotransmission | GABA-A receptor potentiation (calming effect) |
| Cardiac rhythm | Maintains resting membrane potential (antiarrhythmic) |
Magnesium BisglycinateMF
| Application | Dosage (elemental Mg) | Clinical Evidence |
|---|---|---|
| Insomnia (onset/maintenance) | 200–400 mg | Reduces cortisol; improves sleep efficiency and duration |
| Restless leg syndrome | 300–400 mg | Reduces nighttime muscle contractions |
| Age-related sleep decline | 300–500 mg | Restores age-depleted magnesium levels |
Synergistic formulations:
Magnesium glycinate + melatonin + L-theanine (fall asleep faster)
Magnesium glycinate + apigenin + GABA (stay asleep longer)
Magnesium glycinate + glycine (3–5g) + taurine (complete sleep stack)
| Condition | Dosage | Mechanism |
|---|---|---|
| Generalized anxiety | 200–400 mg | GABA potentiation; NMDA antagonism |
| Panic attacks | 300–500 mg | Reduces sympathetic nervous system overactivity |
| Premenstrual syndrome (PMS) | 200–300 mg | Reduces mood swings, irritability, fluid retention |
| Mild depression (as adjunct) | 300–500 mg | Modulates HPA axis; reduces neuroinflammation |
Differentiation opportunity: Magnesium glycinate is the preferred form for mental wellness products due to glycine’s additional calming effect—oxide and citrate lack this property.
| Application | Dosage | Clinical Evidence |
|---|---|---|
| Osteopenia/osteoporosis prevention | 300–500 mg | Parathyroid hormone regulation; osteoblast activity |
| Postmenopausal bone loss | 400–600 mg | Slows bone resorption (synergistic with vitamin D3 and K2) |
| Fracture recovery | 300–500 mg | Collagen synthesis support |
| Application | Dosage | Mechanism |
|---|---|---|
| Hypertension | 300–500 mg | Vasodilation; aldosterone suppression |
| Type 2 diabetes | 300–600 mg | Insulin sensitivity improvement |
| Cardiac arrhythmia | 400–800 mg (medical supervision) | Potassium channel stabilization |
| Migraine prevention | 400–600 mg | NMDA receptor modulation; cortical spreading depression inhibition |
| Application | Dosage | Evidence Base |
|---|---|---|
| Muscle cramp prevention | 300–400 mg | Reduces exercise-associated cramps |
| Post-exercise recovery | 300–500 mg | Reduces creatine kinase (muscle damage marker) |
| Sleep quality (athletes) | 300–500 mg | Enhanced overnight recovery |
| Strength/power sports | 400–600 mg | ATP regeneration support |
| Parameter | Specification | Test Method |
|---|---|---|
| Assay (elemental Mg) | 14.0–20.0% (typically 15–17%) | Titration / ICP-OES |
| Glycine content | 80–86% | HPLC |
| Appearance | White to off-white powder | Visual |
| Bulk density (tapped) | 0.4–0.7 g/mL | USP <616> |
| Loss on Drying | ≤ 5.0% | USP <731> |
| pH (1% solution) | 6.0–8.0 | USP <791> |
| Heavy Metals | Pb ≤ 1 ppm; As ≤ 1 ppm; Cd ≤ 1 ppm; Hg ≤ 0.1 ppm | ICP-MS |
| Chloride (Cl) | ≤ 1.0% | Titration |
| Sulfate (SO₄) | ≤ 0.5% | Turbidimetric |
| Arsenic (As) | ≤ 1 ppm | ICP-MS |
Packaging:
25 kg net fiber drums with double PE liners (industry bulk standard)
1–5 kg aluminum foil bags (sample/trial quantities)
Custom retail packaging (private label jars, pouches, stick packs)
| Barrier | How Oxide/Citrate Fail | How Glycinate Succeeds |
|---|---|---|
| Gastric pH | Converts to poorly absorbed MgCl₂ | Chelate remains intact |
| Dietary inhibitors (phytates, oxalates) | Binds free Mg²⁺ → insoluble precipitate | Chelated Mg protected from binding |
| Intestinal competition (Ca, Zn, Fe) | Competes for same transporters | Uses distinct dipeptide transporter (PepT1) |
| Unabsorbed fraction | Causes osmotic diarrhea | Minimal unabsorbed magnesium |
Ready to formulate with the most bioavailable magnesium on the market?
📧 Email: info@lyvbio.com
🌐 Website: https://www.lyvbio.com
Request your sample today. Experience the LyvBio difference.
English English 
Russian
French
Korean